Drugs / NanoFlu
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03293498 | Sep 2017 → Mar 2018 | influenza | Novavax | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03658629 | Sep 2018 → Apr 2019 | influenza | Novavax | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04120194 | Oct 2019 → Oct 2020 | influenza | Novavax | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NanoFlu | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04120194 ↗ |
| Known as | Quad-NIV | “Biological: NanoFlu (Quad-NIV)” NCT03658629 ↗ |
| Modality | Vaccine | “recombinant hemagglutinin (HA) quadrivalent nanoparticle influenza vaccine (qNIV)” PMID 33146720 ↗ Dec 2021 |
| Route | Intramuscular | “administered an IM injection of NanoFlu” NCT03293498 ↗ |